Antifungal prophylaxis in pediatric hematology/oncology: new choices & new data.

TitleAntifungal prophylaxis in pediatric hematology/oncology: new choices & new data.
Publication TypeJournal Article
Year of Publication2012
AuthorsDvorak CC, Fisher BT, Sung L, Steinbach WJ, Nieder M, Alexander S, Zaoutis TE
JournalPediatr Blood Cancer
Volume59
Issue1
Pagination21-6
Date Published2012 Jul 15
ISSN1545-5017
KeywordsAdolescent, Adult, Antifungal Agents, Child, Child, Preschool, Female, Hematologic Neoplasms, Humans, Infant, Male, Mycoses, Risk Factors
Abstract

A severe complication of the treatment of pediatric cancers is the development of an invasive fungal infection (IFI). The data to support antifungal prophylaxis in pediatric oncology patients derive primarily from adult patients, and thus the optimal agent to utilize is not clear. Fluconazole has been a standard option, but agents with antimold activity are now available, each with limitations. Pediatric dosing for voriconazole and posaconazole is uncertain and multiple drug interactions exist. The echinocandins are well-tolerated, but only available in intravenous form. Ultimately, studies demonstrating biologic risk factors for the development of IFI may lead to personalized prophylactic strategies.

DOI10.1002/pbc.23415
Alternate JournalPediatr Blood Cancer
PubMed ID22102607
PubMed Central IDPMC4008331
Grant ListU10 CA095861 / CA / NCI NIH HHS / United States
U10 CA098543 / CA / NCI NIH HHS / United States
U10 CA98543-08 / CA / NCI NIH HHS / United States
/ / Canadian Institutes of Health Research / Canada